But_home
But_blogshome
But_forum
Icon_rss_infobarSubscribe to receive updates
on new articles and posts from this blog.
 
Latest 5 articles from heartwire

CURRENT OASIS-7: Doubling the clopidogrel dose in ACS patients undergoing PCI

Posted Oct 22, 2009 at 09:30 AM, EDT by Samuel Goldhaber

The CURRENT OASIS-7 trial published during ESC showed a remarkable reduction in myocardial infarction and in-stent thrombosis for patients whose loading dose of clopidogrel was doubled. With a dataset of over 17,000 patients, the results are remarkable and uptake in cath labs has been rapid. With time, how will the OASIS-7 regimen compare with novel antiplatelet agents and approaches to antiplatelet testing?

See:

CURRENT OASIS-7: Benefit to doubling clopidogrel dose in ACS patients undergoing PCI

1 comment1 commentaire | Post a comment | Permalink

CommentsCommentaires

What I think that doubling the dose may causes unavoidable bleeding in the responder. Because still you need some platelet function, for those who are not responding it is wasting of money. So what I suggest, is ,the dose should be platelet -function guided

 
Posted by asuwaidi, Oct 28, 2009 Publié le asuwaidi, 10.28.2009
Reply to this comment

Add your own commentsFaire un commentaire



 



Also from theheart.org
Topol and Teirstein: The Click and Rub Show
This week in cardiology from heartwire
Topolog
The Bob Harrington Show
Private practice with Dr Seth Bilazarian
Fellows' corner
Heartfelt with Dr Melissa Walton-Shirley
Blogs I read


Who's Talking
Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA